Allogene Therapeutics Inc (NASDAQ: ALLO) kicked off on Tuesday, up 3.45% from the previous trading day, before settling in for the closing price of $1.16. Over the past 52 weeks, ALLO has traded in a range of $0.86-$3.78.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 6.26% over the past five years. While this was happening, its average annual earnings per share was recorded 23.59%. With a float of $149.51 million, this company’s outstanding shares have now reached $218.60 million.
Let’s look at the performance matrix of the company that is accounted for 229 employees. In terms of profitability, gross margin is 100.0%, operating margin of 1222209.09%, and the pretax margin is 1144909.09%.
Allogene Therapeutics Inc (ALLO) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Allogene Therapeutics Inc is 31.65%, while institutional ownership is 66.02%. The most recent insider transaction that took place on Jun 10 ’25, was worth 52,377. In this transaction Director of this company sold 36,885 shares at a rate of $1.42, taking the stock ownership to the 107,431 shares. Before that another transaction happened on Jun 10 ’25, when Company’s Director proposed sale 36,885 for $1.42, making the entire transaction worth $52,391.
Allogene Therapeutics Inc (ALLO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.47% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Take a look at Allogene Therapeutics Inc’s (ALLO) current performance indicators. Last quarter, stock had a quick ratio of 9.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.99 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc (NASDAQ: ALLO) saw its 5-day average volume 2.82 million, a negative change from its year-to-date volume of 4.23 million. As of the previous 9 days, the stock’s Stochastic %D was 40.74%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 11.58%, which indicates a significant decrease from 32.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0871 in the past 14 days, which was lower than the 0.1662 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2745, while its 200-day Moving Average is $1.9211. Nevertheless, the first resistance level for the watch stands at $1.2432 in the near term. At $1.2864, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3228. If the price goes on to break the first support level at $1.1636, it is likely to go to the next support level at $1.1272. Assuming the price breaks the second support level, the third support level stands at $1.0840.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
The company with the Market Capitalisation of 262.48 million has total of 218,731K Shares Outstanding. Its annual sales at the moment are 20 K in contrast with the sum of -257,590 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -59,730 K.
